Valion Bio, Inc. VBIO
Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2021 · data as of November 13, 2026
Valion Bio, Inc. (VBIO) is a healthcare company listed in the US with a market value of about $1M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -111%.
About Valion Bio
Valion Bio is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2021. Revenue went from $1M in 2021 to $780000 in 2024, a decline of about 14.7% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 20198% over three years (dilution for shareholders).
Score: 0.2 / 5
Checks passed
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | $780000 | $1M | $2M | $1M |
| Net income | -$9M | -$6M | -$8M | -$10M | -$8M |
| Free cash flow | -$7M | -$6M | -$9M | -$9M | — |
| EPS (diluted) | $-7.84 | $-19.68 | $-176.80 | $-1773.42 | $-4128.90 |
| Net margin | — | -725.0% | -701.0% | -548.7% | -675.7% |
| ROIC | -26.8% | -139.5% | -164.9% | -191.8% | -31.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Valion Bio pay a dividend?
Not currently.
Is Valion Bio a good stock to buy?
We do not give buy or sell advice. Valion Bio scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.